Evidence map›Paper›PMID 38849776›Full record

ArticleBMC biotechnology2024

Microvesicles-delivering Smad7 have advantages over microvesicles in suppressing fibroblast differentiation in a model of Peyronie's disease.

Wenting Wang, Fengchun Wan, Tianxi Yu, Shuang Wu, Xin Cui, Chongjun Xiang, Monong Li, Qingzuo Liu, Chunhua Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenting Wang *Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.
Fengchun Wan *Organ Transplant Center, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.
Tianxi Yu *School of Clinical Medicine, Weifang Medical University, Weifang, 261042, China.
Shuang WuDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.
Xin CuiSchool of Clinical Medicine, Weifang Medical University, Weifang, 261042, China.
Chongjun XiangDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.
Monong LiDepartment of Urology, Qingdao Municipal Hospital, Qingdao, 266011, China.
Qingzuo LiuDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China. ythuianliu@sina.com.
Chunhua LinDepartment of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China. urologylch@qdu.edu.cn.

Funding

the Taishan Scholar Program Tsqn202103198the Yantai Key Research and Development Project 2023YD026
6 · The paper itself

Abstract

backgroundThis study compared the differences of microvesicles (MVs) and microvesicles-delivering Smad7 (Smad7-MVs) on macrophage M1 polarization and fibroblast differentiation in a model of Peyronie's disease (PD).

methodsOverexpression of Smad7 in rat BMSCs was obtained by pCMV5-Smad7 transfection. MVs were collected from rat BMSCs using ultracentrifugation. In cells, 100 µg/mL of MVs or Smad7-MVs were used to treat the 100 ng/mL of lipopolysaccharide (LPS)-induced RAW264.7 cells or 10 ng/mL of recombinant transforming growth factor-β1 (TGF-β1)-induced fibroblasts. The pro-inflammatory cytokines and markers of M1 macrophages were measured in RAW264.7 cells, and the migration and markers of fibroblast differentiation were measured in fibroblasts. In rats, 50 µg of MVs or Smad7-MVs were used to treat the TGF-β1-induced animals. The pathology of tunica albuginea (TA), the markers of M1 macrophages and fibroblast differentiation in the TA were measured.

resultsThe MVs or Smad7-MVs treatment suppressed the LPS-induced macrophage M1 polarization and TGF-β1-induced fibroblast differentiation. Moreover, the Smad7-MVs treatment decreased the fibroblast differentiation compared with the MVs treatment. In the TGF-β1-induced TA of rats, MVs or Smad7-MVs treatment ameliorated the TA fibrosis by suppressing the macrophage M1 polarization and fibroblast differentiation. There was no significance on the M1-polarized macrophages between the MVs treatment and the Smad7-MVs treatment. Meanwhile, the Smad7-MVs treatment had an edge in terms of suppressing the fibroblast differentiation in the TGF-β1-induced PD model compared with the MVs treatment.

conclusionsThis study demonstrated that Smad7-MVs treatment had advantages over MVs treatment in suppressing of fibroblast differentiation in a model of PD.

Indexed as

Cell-Derived MicroparticlesCell DifferentiationDisease Models, AnimalFibroblastsMacrophagesPenile IndurationSmad7 ProteinTransforming Growth Factor beta1AnimalsMaleMesenchymal Stem CellsMiceRatsRats, Sprague-DawleyRAW 264.7 CellsSmad7 ProteinSmad7 protein, ratTransforming Growth Factor beta1Fibroblast differentiationM1 macrophagesMicrovesiclesPeyronie’s disease

Identifiers

PMID38849776
PMCPMC11162046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.